Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1813-1819

  Alhosin, Mahmoud ^a   Ibrahim, Abdulkhaleg ^a   Boukhari, Abdelaziz ^a   Sharif, Tanveer ^a   Gies, Jean Pierre ^a   Auger, Cyril ^a   Schini Kerth, Valérie B ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Faculté de Pharmacie   (France)

Author keywords

Apoptosis; Microtubule; Natural product; Thymoquinone; Tumor suppressor gene p73

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; PROTEIN P73; THYMOQUINONE;

APOPTOSIS; ARTICLE; ASTROCYTOMA CELL; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SPECIFICITY; FIBROBLAST; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTOMA; BENZOQUINONES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FIBROBLASTS; HUMANS; JURKAT CELLS; NUCLEAR PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEOLYSIS; TUBULIN; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84867890420     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9734-1     Document Type: Article

References (44)

1. Zhou J, Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agent 5:65-71. doi: 10.2174/ 1568011053352569
2. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265. doi: 10.1038/nrc1317
3. Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803. doi: 10.1038/nrd3253
4. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116:824-829. doi: 10.1002/ijc.21013
5. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64:4927-4930. doi: 10.1158/0008-5472.CAN-03-3111
6. Canta A, Chiorazzi A, Cavaletti G (2009) Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 16:1315-1324
7. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66:218-228. doi: 10.1016/j.critrevonc.2008.01.008
8. Vats T, Buchanan G, Mehta P, Ragab A, Hvizdale E, Nitschke R, Link M, Beardsley GP, Maybee D, Krischer J (1992) A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. Invest New Drugs 10:231-234
9. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461. doi: 10.1200/JCO.2008.20.5534
10. Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 42:24-30. doi: 10.1016/j.ejca.2005.06.030
11. Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller P, Falette N, Puisieux A, Ann Jordan M, Dumontet C (2003) Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 88:1793-1799. doi: 10.1038/sj.bjc.6600960
12. Alhosin M, Abusnina A, Achour M, Sharif T, Muller CM, Peluso JP, Chataigneau T, Lugnier C, Schini-Kerth VB, Bronner C, Fuhrmann G (2010) Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol 79:1251-1260. doi: 10.1016/j.bcp.2009.12.015
13. Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB, Bronner C (2011) Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 30:41. doi: 10.1186/1756-9966-30-41
14. Abusnina A, Alhosin M, Keravis T, Muller CM, Fuhrmann G, Bronner C, Lugnier C (2011) Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell Signal 23:152-160. doi: 10.1016/j.cellsig.2010.08.015
15. Banerjeea S, Padhyea S, Azmia A, Wanga Z, Philipa PA, Kucukb O, Sarkara FH, Mohammada RM (2010) Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer. Nutrition and Cancer 62:938-946. doi: 10.1080/01635581.2010.509832
16. Gali-Muhtasib H, Roessner A, Schneider-Stock R (2006) Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 38:1249-1253. doi::10.1016/j.biocel.2005.10.009
17. Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK (2003) In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol 22:107-113
18. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA (2005) Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer 117:409-417. doi: 10.1002/ijc.21205
19. Roepke M, Diestel A, Bajbouj K, Walluscheck D, Schonfeld P, Roessner A, Schneider-Stock R, Gali-Muhtasib H (2007) Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther 6:160-169. doi: 10.4161/cbt.6.2.3575
20. Irwin MS, Kaelin WG (2001) Role of the newer p53 family proteins in malignancy. Apoptosis 6:17-29. doi: 10.1023/A:1009663809458
21. Melino G, De Laurenzi V, Vousden KH (2002) p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2:605-615. doi: 10.1038/nrc861
22. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, Frolova EI, Kovriga I, Gudkov AV, Feinstein E, Chumakov PM (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci 105:6302-6307. doi: 10.1073/pnas.0802091105
23. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG (2005) PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24:3484-3491. doi: 10.1038/sj.onc.1208419
24. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK (2007) Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26:3473-3481. doi: 10.1038/sj.onc.1210136
25. Peirce SK, Findley HW (2009) The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 34:1395-1402. doi: 10.3892/ijo-00000267
26. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W (2009) Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113:3744-3753. doi: 10.1182/blood-2008-09-178707
27. Achour M, Jacq X, Rondé P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, Schini-Kerth VB, Bronner C (2008) The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27:2187-2197. doi: 10.1038/sj.onc.1210855
28. Schaefer KL (2008) PPARgamma Inhibitors as Novel Tubulin-Targeting Agents. PPAR Res 2008:785405. doi: 10.1155/2008/785405
29. Gali-Muhtasib H, Kuester D, Mawrin C, Bajbouj K, Diestel A, Ocker M, Habold C, Foltzer-Jourdainne C, Schoenfeld P, Peters B, Diab-Assaf M, Pommrich U, Itani W, Lippert H, Roessner A, Schneider-Stock R (2008) Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res 68:5609-5618. doi: 10.1158/0008-5472.CAN-08-0884
30. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H (2010) Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res 29:87. doi: 10.1186/1756-9966-29-87
31. Tien AL, Senbanerjee S, Kulkarni A, Mudbhary R, Goudreau B, Ganesan S, Sadler KC, Ukomadu C (2011) UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis. Biochem J 435:175-185. doi: 10.1041/BJ20100840
32. DeLuca JG, Moree B, Hickey JM, Kilmartin JV, Salmon ED (2002) hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. J Cell Biol 159:549-555. doi: 10.1083/jcb.200208159
33. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506-526
34. Niikura Y, Dixit A, Scott R, Perkins G, Kitagawa K (2007) BUB1 mediation of caspase-independent mitotic death determines cell fate. J Cell Biol 178:283-296. doi: 10.1083/jcb.200702134
35. Kitagawa K, Niikura Y (2008) Caspase-independent mitotic death (CIMD). Cell Cycle 7:1001-1005. http://dx.doi.org/10.4161/cc.7.8.5720
36. Mi L, Gan N, Cheema A, Dakshanamurthy S, Wang X, Yang DC, Chung FL (2009) Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes. J Biol Chem 284:17039-17051. doi: 10.1074/jbc.M901789200
37. Harris G, Schaefer KL (2009) The microtubule-targeting agent T0070907 induces proteasomal degradation of tubulin. Biochem Biophys Res Commun 388:345-349. doi: 10.1016/j.bbrc.2009.08.009
38. Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T (2008) Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Bio l 15:459-466. doi: 10.1016/j.chembiol.2008.03.013
39. Effenberger-Neidnicht K, Breyer S, Mahal K, Diestel R, Sasse F, Schobert R (2011) Cellular localisation of antitumoral 6-alkyl thymoquinones revealed by an alkyne-azide click reaction and the streptavidin-biotin system. ChemBioChem 12:1237-1241. doi: 10.1002/cbic.201000762
40. Tekeoglu I, Dogan A, Ediz L, Budancamanak M, Demirel A (2007) Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res 21:895-897. doi: 10.1002/ptr.2143
41. Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA (2009) Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 11:373-381. doi: 10.1111/j.1477-2574.2009.00059.x
42. Al-Majed AA, Al-Omar FA, Nagi MN (2006) Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur J Pharmacol 543:40-47. doi: 10.1016/j.ejphar.2006.05.046
43. Kanter M (2011) Protective effects of thymoquinone on the neuronal injury in frontal cortex after chronic toluene exposure. J Mol Histol 42:39-46. doi: 10.1007/s10735-010-9305-3
44. Gurung RL, Lim SN, Khaw AK, Soon JF, Shenoy K, Mohamed Ali S, Jayapal M, Sethu S, Baskar R, Hande MP (2010) Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One 5:e12124. doi: 10.1371/journal.pone.0012124